ArticleFrontiers in oncology2026
ERα36 is associated with SLC7A5/LAT1 expression, cervical cancer progression, and BNCT response: a translational study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To elucidate the role and molecular mechanism of the ERα36-SLC7A5/LAT1 signaling axis in the malignant progression of cervical cancer and its sensitivity to boron neutron capture therapy (BNCT). Methods: Transcriptomic data from TCGA (n=296) and GTEx (n=10) were integrated to analyze SLC7A5 expression and its clinicopathological associations. Multiplex immunofluorescence staining was performed on a tissue microarray containing 99 cervical cancer specimens for spatial phenotyping. SiHa cell lines with stable ERα36 knockdown or overexpression were established using lentiviral transduction. CCK-8, flow cytometry, wound healing, Transwell, and colony formation assays were used to assess the effects of ERα36 on malignant phenotypes. Co-immunoprecipitation, Western blot, and qRT-PCR were employed to explore the interaction between ERα36 and LAT1 as well as downstream signaling changes. The impact of ERα36 on BNCT sensitivity was evaluated in both cellular and subcutaneous xenograft nude mouse models. Results: SLC7A5 was significantly upregulated in cervical cancer tissues and correlated with M stage and poor prognosis. ERα36 and SLC7A5 exhibited robust spatial co-expression in the tumor microenvironment, and the double-positive phenotype was associated with shorter overall survival (P<0.05). ERα36 interacted with LAT1 and was associated with elevated CD98hc and EGFR expression. Knockdown of ERα36 suppressed proliferation, migration, and colony formation while promoting apoptosis; overexpression produced opposite effects. In BNCT simulation experiments, ERα36 knockdown markedly attenuated BNCT-induced cytotoxicity, as evidenced by increased colony formation, reduced apoptosis, and altered S-phase distribution. Both cellular and animal models consistently showed downregulation of ERα36 and LAT1 protein expression after BNCT. Conclusion: The ERα36-SLC7A5/LAT1 axis associated with malignant phenotypes and BNCT sensitivity in cervical cancer. The ERα36+/SLC7A5+ spatial double-positive phenotype may represent a prognostic biomarker, and ERα36 may serve as a predictive marker for BNCT response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.